The DOI matches its Crossref record; 112 of the 112 references it cites were found in a registry or an index.
Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars
Open accessAbstract
Biologics such as monoclonal antibodies are much more complex than small-molecule drugs, which raises challenging questions for the development and regulatory evaluation of follow-on versions of such biopharmaceutical products (also known as biosimilars) and their clinical use once patent protection for the pioneering biologic has expired. With the recent introduction of regulatory pathways for follow-on versions of complex biologics, the role of analytical technologies in comparing biosimilars with the corresponding reference product is attracting substantial interest in establishing the development requirements for biosimilars. Here, we discuss the current state of the art in analytical technologies to assess three characteristics of protein biopharmaceuticals that regulatory authorities have identified as being important in development strategies for biosimilars: post-translational modifications, three-dimensional structures and protein aggregation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases
Bucciantini, M., Giannoni, E., Chiti, F., Baroni, F., Formigli, L., Zurdo, J., Taddei, N., Ramponi, G., Dobson, C. M., & Stefani, M. (2002) · Nature · doi:10.1038/416507a · Cited by 2,434
Protein Posttranslational Modifications: The Chemistry of Proteome Diversifications
Walsh, C. T., Garneau‐Tsodikova, S., & Gatto, G. J. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200501023 · Cited by 1,604
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
Chung, C. H., Mirakhur, B., Chan, E., Le, Q.-T., Berlin, J., Morse, M., Murphy, B. A., Satinover, S. M., Hosen, J., Mauro, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074943 · Cited by 1,521
Effects of protein aggregates: An immunologic perspective
Rosenberg, A. S. (2006) · The AAPS Journal · doi:10.1208/aapsj080359 · Cited by 1,355
Post-translational modifications in the context of therapeutic proteins
Walsh, G., & Jefferis, R. (2006) · Nature Biotechnology · doi:10.1038/nbt1252 · Cited by 1,005
Protein aggregation: Pathways, induction factors and analysis
Mahler, H.-C., Friess, W., Grauschopf, U., & Kiese, S. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21566 · Cited by 901
Mapping protein post-translational modifications with mass spectrometry
Witze, E. S., Old, W. M., Resing, K. A., & Ahn, N. G. (2007) · Nature Methods · doi:10.1038/nmeth1100 · Cited by 792
Baber, N. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb05705.x · Cited by 759
Biopharmaceutical benchmarks 2010
Walsh, G. (2010) · Nature Biotechnology · doi:10.1038/nbt0910-917 · Cited by 756
Mass spectrometry for proteomics
Han, X., Aslanian, A., & Yates, J. R. (2008) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2008.07.024 · Cited by 734
A systematic approach to protein glycosylation analysis: a path through the maze
Mariño, K., Bones, J., Kattla, J. J., & Rudd, P. M. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.437 · Cited by 628
Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events
Guerrini, M., Beccati, D., Shriver, Z., Naggi, A., Viswanathan, K., Bisio, A., Capila, I., Lansing, J. C., Guglieri, S., Fraser, B., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1407 · Cited by 628
Carpenter, J. F., Randolph, T. W., Jiskoot, W., Crommelin, D. J. A., Russell Middaugh, C., Winter, G., Fan, Y.-X., Kirshner, S., Verthelyi, D., Kozlowski, S., et al. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21530 · Cited by 595
Bioequivalence and the immunogenicity of biopharmaceuticals
Schellekens, H. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd818 · Cited by 534
Decoding protein modifications using top-down mass spectrometry
Siuti, N., & Kelleher, N. L. (2007) · Nature Methods · doi:10.1038/nmeth1097 · Cited by 503
Acceptable changes in quality attributes of glycosylated biopharmaceuticals
Schiestl, M., Stangler, T., Torella, C., Čepeljnik, T., Toll, H., & Grau, R. (2011) · Nature Biotechnology · doi:10.1038/nbt.1839 · Cited by 473
Protein Complexes in the Gas Phase: Technology for Structural Genomics and Proteomics
Benesch, J. L. P., Ruotolo, B. T., Simmons, D. A., & Robinson, C. V. (2007) · Chemical Reviews · doi:10.1021/cr068289b · Cited by 408
Analysis of protein glycosylation by mass spectrometry
Morelle, W., & Michalski, J.-C. (2007) · Nature Protocols · doi:10.1038/nprot.2007.227 · Cited by 394
Post-translational Modifications Differentially Affect IgG1 Conformation and Receptor Binding
Houde, D., Peng, Y., Berkowitz, S. A., & Engen, J. R. (2010) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m900540-mcp200 · Cited by 393
Self-citationHoude, D., Berkowitz, S. A., & Engen, J. R. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22432 · Cited by 375
Self-citationImmunogenicity of protein therapeutics: The key causes, consequences and challenges
Baker, M., Reynolds, H. M., Lumicisi, B., & Bryson, C. J. (2010) · Self/Nonself · doi:10.4161/self.1.4.13904 · Cited by 372
Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins
Ghaderi, D., Taylor, R. E., Padler-Karavani, V., Diaz, S., & Varki, A. (2010) · Nature Biotechnology · doi:10.1038/nbt.1651 · Cited by 372
Analysis of Protein Conformation and Dynamics by Hydrogen/Deuterium Exchange MS
Engen, J. R. (2009) · Analytical Chemistry · doi:10.1021/ac901154s · Cited by 369
Self-citationImpact of Product-Related Factors on Immunogenicity of Biotherapeutics
Singh, S. K. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22276 · Cited by 350
Strategies for the assessment of protein aggregates in pharmaceutical biotech product development
den Engelsman, J., Garidel, P., Smulders, R., Koll, H., Smith, B., Bassarab, S., Seidl, A., Hainzl, O., & Jiskoot, W. (2011) · Pharmaceutical Research · doi:10.1007/s11095-010-0297-1 · Cited by 348
Singh, S. K., Afonina, N., Awwad, M., Bechtold-Peters, K., Blue, J. T., Chou, D., Cromwell, M., Krause, H.-J., Mahler, H.-C., Meyer, B. K., et al. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22097 · Cited by 334
Mass spectrometry for structural characterization of therapeutic antibodies
Zhang, Z., Pan, H., & Chen, X. (2009) · Mass Spectrometry Reviews · doi:10.1002/mas.20190 · Cited by 316
Principles, approaches, and challenges for predicting protein aggregation rates and shelf life
Weiss, W. F., Young, T. M., & Roberts, C. J. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21521 · Cited by 308
Probing Protein Ligand Interactions by Automated Hydrogen/Deuterium Exchange Mass Spectrometry
Chalmers, M. J., Busby, S. A., Pascal, B. D., He, Y., Hendrickson, C. L., Marshall, A. G., & Griffin, P. R. (2006) · Analytical Chemistry · doi:10.1021/ac051294f · Cited by 301
Determination of glycosylation sites and site-specific heterogeneity in glycoproteins
An, H. J., Froehlich, J. W., & Lebrilla, C. B. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.07.022 · Cited by 280
Differential hydrogen/deuterium exchange mass spectrometry analysis of protein–ligand interactions
Chalmers, M. J., Busby, S. A., Pascal, B. D., West, G. M., & Griffin, P. R. (2011) · Expert Review of Proteomics · doi:10.1586/epr.10.109 · Cited by 252
Is any measurement method optimal for all aggregate sizes and types?
Philo, J. S. (2006) · The AAPS Journal · doi:10.1208/aapsj080365 · Cited by 245
Takamoto, K., & Chance, M. R. (2006) · Annual Review of Biophysics and Biomolecular Structure · doi:10.1146/annurev.biophys.35.040405.102050 · Cited by 245
Arakawa, T., Ejima, D., Li, T., & Philo, J. S. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21974 · Cited by 224
Rand, K. D., Zehl, M., Jensen, O. N., & Jørgensen, T. J. D. (2009) · Analytical Chemistry · doi:10.1021/ac9008447 · Cited by 220
Isoaspartyl Post-translational Modification Triggers Autoimmune Responses to Self-proteins
Mamula, M. J., Gee, R. J., Elliott, J. I., Sette, A., Southwood, S., Jones, P.-J., & Blier, P. R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.32.22321 · Cited by 212
Houde, D., Arndt, J., Domeier, W., Berkowitz, S., & Engen, J. R. (2009) · Analytical Chemistry · doi:10.1021/ac802575y · Cited by 206
Self-citationCarpenter, J. F., Randolph, T. W., Jiskoot, W., Crommelin, D. J. A., Middaugh, C. R., & Winter, G. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21989 · Cited by 202
Liu, J., Andya, J. D., & Shire, S. J. (2006) · The AAPS Journal · doi:10.1208/aapsj080367 · Cited by 202
Worldwide experience with biosimilar development
McCamish, M., & Woollett, G. (2011) · mAbs · doi:10.4161/mabs.3.2.15005 · Cited by 199
A critical review of methods for size characterization of non-particulate protein aggregates
Philo, J. (2009) · Current Pharmaceutical Biotechnology · doi:10.2174/138920109788488815 · Cited by 196
Aggregation of Therapeutic Proteins
(2010) · Wiley eBooks · doi:10.1002/9780470769829 · Cited by 195
Developing the Nation's Biosimilars Program
Kozlowski, S., Woodcock, J., Midthun, K., & Behrman Sherman, R. (2011) · New England Journal of Medicine · doi:10.1056/nejmp1107285 · Cited by 194
Methods for structural analysis of protein pharmaceuticals
Jiskoot, W., & Crommelin, D. J. A. (2005) · Cited by 181
Scarff, C. A., Thalassinos, K., Hilton, G. R., & Scrivens, J. H. (2008) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.3737 · Cited by 178
Gabrielson, J. P., Brader, M. L., Pekar, A. H., Mathis, K. B., Winter, G., Carpenter, J. F., & Randolph, T. W. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20760 · Cited by 175
Srebalus Barnes, C. A., & Lim, A. (2007) · Mass Spectrometry Reviews · doi:10.1002/mas.20129 · Cited by 175
A Critical Review of Analytical Methods for Subvisible and Visible Particles
Narhi, L. O., Jiang, Y., Cao, S., Benedek, K., & Shnek, D. (2009) · Current Pharmaceutical Biotechnology · doi:10.2174/138920109788488905 · Cited by 152
Xie, H., Chakraborty, A. B., Ahn, J., Yu, Y. Q., Deepalakshmi, P. D., Gilár, M., Chen, W., Skilton, S. J., & Mazzeo, J. R. (2010) · mAbs · doi:10.4161/mabs.11986 · Cited by 151
Self-citationCollisions or Electrons? Protein Sequence Analysis in the 21st Century
Coon, J. J. (2009) · Analytical Chemistry · doi:10.1021/ac802330b · Cited by 151
Kaltashov, I. A., Bobst, C. E., Abzalimov, R. R., Wang, G., Baykal, B., & Wang, S. (2011) · Biotechnology Advances · doi:10.1016/j.biotechadv.2011.05.006 · Cited by 149
Immunogenicity of therapeutic proteins
Schellekens, H. (2003) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfg164 · Cited by 148
Taking immunogenicity assessment of therapeutic proteins to the next level
Büttel, I., Chamberlain, P., Chowers, Y., Ehmann, F., Greinacher, A., Jefferis, R., Kramer, D., Kropshofer, H., Lloyd, P. M., Lubiniecki, A. S., et al. (2011) · Biologicals · doi:10.1016/j.biologicals.2011.01.006 · Cited by 145
Role of analytical ultracentrifugation in assessing the aggregation of protein biopharmaceuticals
Berkowitz, S. A. (2006) · The AAPS Journal · doi:10.1208/aapsj080368 · Cited by 140
Self-citationWu, S., Jiang, H., Lu, Q., Dai, S., Hancock, W. S., & Karger, B. L. (2008) · Analytical Chemistry · doi:10.1021/ac801560k · Cited by 138
Jaisson, S., & Gillery, P. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2010.145201 · Cited by 137
Microscale LC-MS-NMR Platform Applied to the Identification of Active Cyanobacterial Metabolites
Lin, Y., Schiavo, S., Orjala, J., Vouros, P., & Kautz, R. A. (2008) · Analytical Chemistry · doi:10.1021/ac801049k · Cited by 124
Kaletaş, B. K., Filipe, V., van Duijn, E., Kasper, P. T., Vreeken, R. J., Heck, A. J. R., & Jiskoot, W. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0224-5 · Cited by 120
Bagal, D., Zhang, H., & Schnier, P. D. (2008) · Analytical Chemistry · doi:10.1021/ac7020163 · Cited by 113
Characterization of Particles in Protein Solutions: Reaching the Limits of Current Technologies
Demeule, B., Messick, S., Shire, S. J., & Liu, J. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9233-x · Cited by 113
Hydrogen Exchange Mass Spectrometry: Are We Out of the Quicksand?
Iacob, R. E., & Engen, J. R. (2012) · Journal of the American Society for Mass Spectrometry · doi:10.1007/s13361-012-0377-z · Cited by 112
Self-citationStructure elucidation of native N‐ and O‐linked glycans by tandem mass spectrometry (tutorial)
An, H. J., & Lebrilla, C. B. (2010) · Mass Spectrometry Reviews · doi:10.1002/mas.20283 · Cited by 111
Wang, Y., Lu, Q., Wu, S., Karger, B. L., & Hancock, W. S. (2011) · Analytical Chemistry · doi:10.1021/ac200128d · Cited by 111
Ni, W., Dai, S., Karger, B. L., & Zhou, Z. S. (2010) · Analytical Chemistry · doi:10.1021/ac101806e · Cited by 109
Chapter 40 Identification and Quantification of Protein Posttranslational Modifications
Farley, A. R., & Link, A. J. (2009) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(09)63040-8 · Cited by 108
Aggregation of therapeutic proteins
Wang, W., & Roberts, C. J. (2010) · Wiley eBooks · Cited by 104
Bagal, D., Valliere‐Douglass, J. F., Balland, A., & Schnier, P. D. (2010) · Analytical Chemistry · doi:10.1021/ac1013139 · Cited by 102
Rand, K. D., Pringle, S. D., Murphy, J. P., Fadgen, K. E., Brown, J. M., & Engen, J. R. (2009) · Analytical Chemistry · doi:10.1021/ac901897x · Cited by 101
Self-citationHokke, C. H., Bergwerff, A. A., van Dedem, G. W. K., van Oostrum, J., Kamerling, J. P., & Vliegenthart, J. F. G. (1990) · FEBS Letters · doi:10.1016/0014-5793(90)81427-p · Cited by 101
Kellie, J. F., Tran, J. C., Lee, J. E., Ahlf, D. R., Thomas, H. M., Ntai, I., Catherman, A. D., Durbin, K. R., Zamdborg, L., Vellaichamy, A., et al. (2010) · Molecular BioSystems · doi:10.1039/c000896f · Cited by 99
Development and Validation of an NMR-Based Identity Assay for Bacterial Polysaccharides
Abeygunawardana, C., Williams, T. C., Sumner, J. S., et al. (2000) · Analytical Biochemistry · doi:10.1006/abio.1999.4470 · Cited by 98
Immunogenicity of therapeutic proteins. Part 2: Impact of container closures
Sharma, B. (2007) · Biotechnology Advances · doi:10.1016/j.biotechadv.2007.01.006 · Cited by 98
Li, X., Lin, C., & O’Connor, P. B. (2010) · Analytical Chemistry · doi:10.1021/ac9028467 · Cited by 96
Immunogenicity of therapeutic proteins. Part 3: Impact of manufacturing changes
Sharma, B. (2007) · Biotechnology Advances · doi:10.1016/j.biotechadv.2007.01.007 · Cited by 95
Kaltashov, I. A., Bobst, C. E., Abzalimov, R. R., Berkowitz, S. A., & Houde, D. J. (2009) · Journal of the American Society for Mass Spectrometry · doi:10.1016/j.jasms.2009.10.013 · Cited by 93
Self-citationAltered immunogenicity of isoaspartate containing proteins
Doyle, H. A., Gee, R. J., & Mamula, M. J. (2007) · Autoimmunity · doi:10.1080/08916930601165180 · Cited by 92
Borys, M., Dalal, N. G., Abu‐Absi, N. R., Khattak, S. F., Jing, Y., Xing, Z., & Li, Z. J. (2009) · Biotechnology and Bioengineering · doi:10.1002/bit.22644 · Cited by 89
Lubiniecki, A. S., Volkin, D. B., Federici, M. M., Bond, M. D., Nedved, M. L., Hendricks, L. C., Mehndiratta, P., Bruner, M. W., Burman, S., Dalmonte, P., et al. (2010) · Biologicals · doi:10.1016/j.biologicals.2010.08.004 · Cited by 87
Structure of IL-17A in Complex with a Potent, Fully Human Neutralizing Antibody
Gerhardt, S., Abbott, W. M., Hargreaves, D., Pauptit, R. A., Davies, R. A., Needham, M., Langham, C., Barker, W., Aziz, A., Snow, M. J., et al. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.10.008 · Cited by 84
Pekar, A. H., & Sukumar, M. (2007) · Analytical Biochemistry · doi:10.1016/j.ab.2007.04.035 · Cited by 83
Sargaeva, N. P., Lin, C., & O’Connor, P. B. (2009) · Analytical Chemistry · doi:10.1021/ac901677t · Cited by 83
Atmanène, C., Wagner‐Rousset, E., Malissard, M., Chol, B., Robert, A., Corvaı̈a, N., DORSSELAER, A. V., Beck, A., & Cianférani, S. (2009) · Analytical Chemistry · doi:10.1021/ac9007557 · Cited by 82
Immunogenicity of therapeutic proteins. Part 1: Impact of product handling
Sharma, B. (2007) · Biotechnology Advances · doi:10.1016/j.biotechadv.2007.01.005 · Cited by 73
Chen, G., Warrack, B. M., Goodenough, A. K., Wei, H., Wang‐Iverson, D. B., & Tymiak, A. A. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.11.003 · Cited by 73
Wen, D., Vecchi, M. M., Gu, S., Su, L., Dolníková, J., Huang, Y., Foley, S. F., Garber, E. A., Pederson, N. E., & Meier, W. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.059360 · Cited by 70
Deechongkit, S., Aoki, K. H., Park, S. S., & Kerwin, B. A. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20649 · Cited by 68
Carpenter, J. P., Cherney, B., Lubinecki, A., Ma, S., Marszal, E., Mire‐Sluis, A. R., Nikolai, T. J., Novak, J. M., Ragheb, J. A., & Šimák, J. (2010) · Biologicals · doi:10.1016/j.biologicals.2010.07.002 · Cited by 67
Aubin, Y., Gingras, G., & Sauvé, S. (2008) · Analytical Chemistry · doi:10.1021/ac7026222 · Cited by 65
Misbehaving proteins : protein (mis)folding, aggregation, and stability
Murphy, R. M., & Tsai, A. M. (2006) · doi:10.1007/0-387-36063-8 · Cited by 64
Chan, W. Y. K., Chan, T. ‐. D., & O’Connor, P. B. (2010) · Journal of the American Society for Mass Spectrometry · doi:10.1016/j.jasms.2010.02.002 · Cited by 63
Measuring low levels of protein aggregation by sedimentation velocity
Gabrielson, J. P., & Arthur, K. K. (2010) · Methods · doi:10.1016/j.ymeth.2010.12.030 · Cited by 59
Gabrielson, J. P., Randolph, T. W., Kendrick, B. S., & Stoner, M. R. (2006) · Analytical Biochemistry · doi:10.1016/j.ab.2006.11.012 · Cited by 59
Wei, H., Ahn, J., Yu, Y. Q., et al. (2012) · Journal of the American Society for Mass Spectrometry · doi:10.1007/s13361-011-0310-x · Cited by 59
Arthur, K. K., Gabrielson, J. P., Kendrick, B. S., & Stoner, M. R. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21654 · Cited by 58
Gabrielson, J. P., Arthur, K. K., Stoner, M. R., Winn, B. C., Kendrick, B. S., Razinkov, V., Svitel, J., Jiang, Y., Voelker, P. J., Fernandes, C. A., et al. (2010) · Analytical Biochemistry · doi:10.1016/j.ab.2009.09.036 · Cited by 56
Škrlin, A., Radić, I., Vuletić, M., Schwinke, D. L., Runac, D., Kusalic, T., Paškvan, I., Krsic, M., Bratos, M., & Marinc, S. (2010) · Biologicals · doi:10.1016/j.biologicals.2010.05.002 · Cited by 55
LC-MS for protein characterization: current capabilities and future trends
Chen, G., & Pramanik, B. N. (2008) · Expert Review of Proteomics · doi:10.1586/14789450.5.3.435 · Cited by 55
Jiang, H., Wu, S., Karger, B. L., et al. (2010) · Analytical Chemistry · doi:10.1021/ac100956x · Cited by 55
Borchers, C. H., Thapar, R., Petrotchenko, E. V., Torres, M. P., Speir, J. P., Easterling, M. L., Domiński, Z., & Marzluff, W. F. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511289103 · Cited by 48
Schoenecker, J. G., Hauck, R. K., Mercer, M. C., Parker, W., & Lawson, J. H. (2000) · Journal of Clinical Immunology · doi:10.1023/a:1026455631876 · Cited by 47
Gabrielson, J. P., Arthur, K. K., Kendrick, B. S., Randolph, T. W., & Stoner, M. R. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21403 · Cited by 46
Yang, H., Fung, Y. M. E., Zubarev, A. R., & Zubarev, R. A. (2009) · Journal of Proteome Research · doi:10.1021/pr900428m · Cited by 43
Experimental Detection and Characterization of Protein Aggregates
Sharma, V. K., & Kalonia, D. S. (2010) · Wiley eBooks · doi:10.1002/9780470769829.ch5 · Cited by 32
Mukherjee, R., Adhikary, L., Khedkar, A., & Iyer, H. (2010) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.4464 · Cited by 32
Houde, D. J., & Demarest, S. J. (2011) · Structure · doi:10.1016/j.str.2011.03.014 · Cited by 28
Approaches to the Conformational Analysis of Biopharmaceuticals
Lundblad, R. L. (2009) · Chapman & Hall/CRC eBooks · doi:10.1201/9781439807811 · Cited by 27
Cao, X., Wen, Z., Vance, A., & Torraca, G. (2009) · Applied Spectroscopy · doi:10.1366/000370209788701026 · Cited by 23
Liu, C., Dong, S., Xu, X., Yin, Y., Shriver, Z. H., Capila, I., Myette, J. R., & Venkataraman, G. (2010) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2010.07.044 · Cited by 21
Bobst, C. E., & Kaltashov, I. A. (2011) · Current Pharmaceutical Biotechnology · doi:10.2174/138920111798357311 · Cited by 21
The formulation and immunogenicity of therapeutic proteins: Product quality as a key factor.
Richard, J., & Prang, N. (2010) · PubMed · Cited by 18
Kilgore, B. R., Lucka, A. W., Patel, R., Andrien, B. A., & Dhume, S. T. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-084-7_23 · Cited by 9
Erickson, B. E. (2010) · Chemical & Engineering News · doi:10.1021/cen-v088n048.p025 · Cited by 8
Cited by
Characterization of Therapeutic Antibodies and Related Products
Beck, A., Wagner-Rousset, E., Ayoub, D., Van Dorsselaer, A., & Sanglier-Cianférani, S. (2013) · Analytical Chemistry · doi:10.1021/ac3032355 · Cited by 587
Engineering protein-based therapeutics through structural and chemical design
Ebrahimi, S. B., & Samanta, D. (2023) · Nature Communications · doi:10.1038/s41467-023-38039-x · Cited by 382
Physicochemical characterization of Remsima®
Jung, S. K., Lee, K. H., Jeon, J. W., Lee, J. W., Kwon, B. O., Kim, Y. J., Bae, J. S., Kim, D.-I., Lee, S. Y., & Chang, S. J. (2014) · mAbs · doi:10.4161/mabs.32221 · Cited by 330
James, E. I., Murphree, T. A., Vorauer, C., Engen, J. R., & Guttman, M. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00279 · Cited by 305
Self-citationFekete, S., Guillarme, D., Sandra, P., & Sandra, K. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.5b04561 · Cited by 258
Metadata
- Authors
- Berkowitz, S. A., Engen, J. R., Mazzeo, J. R., & Jones, G. B.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2012-06-29
- Volume
- 11
- Issue
- 7
- Pages
- 527-540
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1971014721
- Cited by
- 529
- References
- 112
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.